NEURO360 partner, Avadel Pharmaceuticals, is expanding its sleep medicine pipeline with a new potential therapy, valiloxybate for treatment of narcolepsy and idiopathic hypersomnia. Read the press release at Avadel Pharmaceuticals’ website by clicking here.
NEURO360, BioSTL’s NSF Engines grant application with WashU, faced delays due to federal funding shifts—but we’re back on track. Our commitment to making St. Louis a leader in neuroscience innovation remains strong, regardless of the NSF outcome.
In a recent study, researchers at WashU Medicine found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer’s disease who received lecanemab infusions at the Memory Diagnostic Center at WashU Medicine. Read the entire article on the Washington University Newsroom website by clicking here.
When a person sustains an injury to the spinal cord, the normal communication between the brain and the spinal circuits below the injury are interrupted, resulting in paralysis. Because the brain is functioning normally, as is the spinal cord below the injury, researchers have been working to re-establish the communication to allow for rehabilitation and […]
Opportunity to Secure $160 Million to Establish St. Louis as a Global Neuroscience Leader
Washington University and BioSTL are hoping to transform St. Louis into a global neuroscience leader through its NEURO360 initiative. BioSTL’s CEO Donn Rubin tells Anthony Morabith on Show Me Today that big things are in store for the future of St. Louis. Listen to the Show Me Today interview on the official MissouriNet website by clicking here.
